The company has received $791 million in funding from several prominent technology and health science companies, strategic angel investors, and venture capital firms. Most recently GlaxoSmithKline made a equity investment in 23andMe. Sequoia Capital led the previous round of financing, which included investments from Fidelity Management & Research Company, Euclidean Capital, Altimeter Capital and the Wallenberg Foundation. Fidelity Management led the previous round of financing. Other 23andMe investors include Yuri Milner, Johnson & Johnson Development Corporation (NYSE: JNJ), MPM Capital, The Roche Venture Fund (Swiss: RO.SW ), Google Ventures (NASDAQ: GOOG), New Enterprise Associates., Casdin Capital, WuXi Healthcare Ventures, Xfund, and Illumina (ILMN).